AR072249A1 - Inhibidores de amida hidrolasa de acido graso. usos. metodos. - Google Patents
Inhibidores de amida hidrolasa de acido graso. usos. metodos.Info
- Publication number
- AR072249A1 AR072249A1 ARP090101257A ARP090101257A AR072249A1 AR 072249 A1 AR072249 A1 AR 072249A1 AR P090101257 A ARP090101257 A AR P090101257A AR P090101257 A ARP090101257 A AR P090101257A AR 072249 A1 AR072249 A1 AR 072249A1
- Authority
- AR
- Argentina
- Prior art keywords
- optionally substituted
- alkyl
- independently
- carbocyclyl
- aryl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic System
- C07F5/02—Boron compounds
- C07F5/025—Boronic and borinic acid compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic System
- C07F5/02—Boron compounds
Abstract
Compuestos, y composiciones farmacéuticamente aceptables de ellos, abarcados por cualquiera de las formulas (1), (2), (3), (4), (5) o (6), o sus subgéneros. Métodos para tratar una enfermedad, trastorno o afeccion mediada por FAAH a través de la administracion de una cantidad terapéuticamente efectiva de un compuesto o una composicion que comprende un compuesto de cualquiera de las formulas (1), (2), (3), (4), (5) o (6), o sus subgéneros, a un paciente que lo necesita. Métodos para inhibir FAAH mediante la administracion de una cantidad terapéuticamente efectiva de un compuesto o una composicion que comprende un compuesto de cualquiera de las formulas (1), (2), (3), (4), (5) o (6), o sus subgéneros, a un paciente que lo necesita. Reivindicacion 1: Una composicion farmacéuticamente aceptable que comprende un compuesto de formula (3) o una sal o prodroga farmacéuticamente aceptable de dicho compuesto; en donde: (i) Z1 es -OH o -OR3 y Z2 es -OH, -OR4, un alquilo C1-8 opcionalmente sustituido, alquenilo C2-8 opcionalmente sustituido, alquinilo C2-8 opcionalmente sustituido, heteroalquilo C1-8 opcionalmente sustituido, heteroalquenilo C2-8 opcionalmente sustituido, heteroalquinilo C2-8 opcionalmente sustituido, carbociclilo C3-10 opcionalmente sustituido, heterociclilo de 3-10 miembros opcionalmente sustituido, arilo C6-10 opcionalmente sustituido o heteroarilo de 5-10 miembros opcionalmente sustituido; (ii) Z1 y Z2, tomados junto con el átomo de boro al cual están unidos, forman un anillo de 5 a 8 miembros que tiene al menos un átomo de O, S o NR5 directamente unido al átomo de boro; o (iii) Z1 es -OH o -OR3, y Z2 y el Anillo A tomados juntos forman un anillo de 5 a 7 miembros opcionalmente sustituido; W1 y W2 se seleccionan independientemente de CR12, C y N; X es un enlace covalente, -O-, -N=N-, -C=N-, -NR6-, -C(NR6)-, -S-, -C(O)-, -S(O)-, -S(O)2-, o alquileno C1-6 opcionalmente sustituido, en donde una, dos o tres unidades de metileno del alquileno C1-6 están opcional e independientemente reemplazadas por uno o varios grupos seleccionados de -O-, -N=N-, -C=N-, -NR6-, -C(NR6)-, -S-, -C(O)-, -S(O)- y -S(O)2-; RA es hidrogeno, halogeno, -OR7, -CF3, -CN, -NO2, -SO2R7, -SOR7, -C(O)R7, -CO2R7, -C(O)N(R7)2, -N3, -N2R7, -N(R7)2 o el Anillo B que tiene la formula (7) en donde el Anillo B es carbociclilo C3-10 opcionalmente sustituido, heterociclilo de 3-10 miembros opcionalmente sustituido, arilo C6-10 opcionalmente sustituido o heteroarilo de 5-10 miembros opcionalmente sustituido; cada caso de R1 es, independientemente, halogeno, -OR8, -CF3, -CN, -NO2, -SO2R8, -SOR8, -C(O)R8, -CO2R8, -C(O)N(R8)2, -N3, -N2R8, -N(R8)2, -B(OH2), alquilo C1-8 opcionalmente sustituido, alquenilo C2-8 opcionalmente sustituido, alquinilo C2-8 opcionalmente sustituido, heteroalquilo C1-8 opcionalmente sustituido, heteroalquenilo C2-8 opcionalmente sustituido, heteroalquinilo C2-8 opcionalmente sustituido, carbociclilo C3-10 opcionalmente sustituido, heterociclilo de 3-10 miembros opcionalmente sustituido, arilo C6-10 opcionalmente sustituido, o heteroarilo de 5-10 miembros opcionalmente sustituido; cada caso de R2 es, independientemente, halogeno, -OR9, -CF3, -CN, -NO2, -SO2R9, -SOR9, -C(O)R9, -CO2R9, -C(O)N(R9)2, -N3, -N2R9, -N(R9)2, alquilo C1-8 opcionalmente sustituido, alquenilo C2-8 opcionalmente sustituido, alquinilo C2-8 opcionalmente sustituido, heteroalquilo C1-8 opcionalmente sustituido, heteroalquenilo C2-8 opcionalmente sustituido, heteroalquinilo C2-8 opcionalmente sustituido, carbociclilo C3-10 opcionalmente sustituido, heterociclilo de 3-10 miembros opcionalmente sustituido, ariIo C6-10 opcionalmente sustituido o heteroarilo de 5-10 miembros opcionalmente sustituido; cada caso de R3 y R4 es, independientemente, aIquilo C1-8, opcionalmente sustituido, aIqueniIo C2-8 opcionalmente sustituido, aIquiniIo C2-8 opcionalmente sustituido, heteroalquilo C1-8 opcionalmente sustituido, heteroalquenilo C2-8 opcionalmente sustituido, heteroalquinilo C2-8 opcionalmente sustituido, carbociclilo C3-10 opcionalmente sustituido, heterociclilo de 3-10 miembros opcionalmente sustituido, ariIo C6-10 opcionalmente sustituido o heteroarilo de 5-10 miembros opcional mente sustituido; cada caso de R5, R6, R7, R8, R9 y R10 es, independientemente, hidrogeno, -SO2R11, -SOR11, -C(O)R11, -CO2R11, -C(O)N(R11)2, -C(O)NH(R1 1), alquilo C1-8 opcionalmente sustituido, alquenilo C2-8 opcionalmente sustituido, aIquiniIo C2-8 opcionalmente sustituido, heteroalquilo C1-8 opcionalmente sustituido, heteroalquenilo C2-8 opcionalmente sustituido, heteroalquinilo C2-8 opcionalmente sustituido, carbociclilo C3-10 opcionalmente sustituido, heterociclilo de 3-10 miembros opcionalmente sustituido, ariIo C6-10 opcionalmente sustituido o heteroarilo de 5-10 miembros opcionalmente sustituido; cada caso de R11 es, independientemente, aIquiIo C1-8 opcionalmente sustituido, aIqueniIo C2-8 opcionalmente sustituido, aIquiniIo C2-8 opcionalmente sustituido, heteroalquilo C1-8 opcionalmente sustituido, heteroalquenilo C2-8 opcionalmente sustituido, heteroalquinilo C2-8 opcionalmente sustituido, carbociclilo C3-10 opcionalmente sustituido, heterociclilo de 3-10 miembros opcionalmente sustituido, ariIo C6-10 opcionalmente sustituido o heteroarilo de 5-10 miembros opcionalmente sustituido; cada caso de R12 es, independientemente, hidrogeno, halogeno, -CF3, alquilo C1-8 opcionalmente sustituido, alquenilo C2-8 opcionalmente sustituido o aIquinilo C2-8 opcionalmente sustituido; n es, independientemente, 0, 1, 2 o 3 y m es 0, 1, 2, 3, 4 o 5. Reivindicacion 18: Una composicion farmacéuticamente aceptable que comprende un compuesto de formula (4) o una sal o prodroga farmacéuticamente aceptable de dicho compuesto, en donde: (i) Z1 es -OH o -OR3 y Z2 es -OH, -OR4, un alquilo C1-8 opcionalmente sustituido, alquenilo C2-8 opcionalmente sustituido, alquinilo C2-8 opcionalmente sustituido, heteroalquilo C1-8 opcionalmente sustituido, heteroalquenilo C2-8 opcionalmente sustituido, heteroalquinilo C2-8 opcionalmente sustituido, carbociclilo C3-10 opcionalmente sustituido, heterociclilo de 3-10 miembros opcionalmente sustituido, arilo C6-10 opcionalmente sustituido o heteroarilo de 5-10 miembros opcionalmente sustituido; (ii) Z1 y Z2, tomados junto con el átomo de boro al cual están unidos, forman un anillo de 5 a 8 miembros que tiene al menos un átomo de O, S o NR5 directamente unido al átomo de boro; o (iii) Z1 es -OH o -OR3, y Z2 y el Anillo A tomados juntos forman un anillo de 5 a 7 miembros opcionalmente sustituido; Y3, Y4 y Y5 se selecciona cada uno independientemente de C, CR13, N, NR14, O y S, con la condicion de que al menos uno de Y3, Y4 o Y5 sea un heteroátomo seleccionado de N, NR14, O o S; Y6 es C o N; X es un enlace covalente, -O-, -N=N-, -C=N-, -NR6-, -C(NR6)-, -S-, -C(O)-, -S(O)-, -S(O)2-, o alquileno C1-6 opcionalmente sustituido, en donde una, dos o tres unidades de metileno del alquileno C1-6 están opcional e independientemente reemplazadas con uno o varios grupos seleccionados de -O-, -N=N-, -C=N-, -NR6-, -C(NR6)-, -S-, -C(O)-, -S(O)-, -S(O)2-, Ra es hidrogeno, halogeno, -OR7, -CF3, -CN, -NO2, -SO2R7, -SOR7, - C(O)R7, -CO2R7, -C(O)N(R7)2, -CHO, -N3, -N2R7, -N(R7)2, o el Anillo B que tiene la formula (7) en donde el Anillo B es carbociclilo C3-10 opcionalmente sustituido, heterociclilo de 3-10 miembros opcionalmente sustituido, ariIo C6-10 opcionalmente sustituido o heteroarilo de 5-10 miembros opcionalmente sustituido; cada caso de R1 es, independientemente, halogeno, -OR8, -CF3, -CN, -NO2, -SO2R8, -SOR8, -C(O)R8, -CO2R8, -C(O)N(R8)2, -N3, -N2R8, -N(R8)2, -B(OH2), alquilo C1-8 opcionalmente sustituido, alquenilo C2-8 opcionalmente sustituido, alquinilo C2-8 opcionalmente sustituido, heteroalquilo C1-8 opcionalmente sustituido, heteroalquenilo C2-8 opcionalmente sustituido, heteroalquinilo C2-8 opcionalmente sustituido, carbociclilo C3-10 opcionalmente sustituido, heterociclilo de 3-10 miembros opcionalmente sustituido, arilo C6-10 opcionalmente sustituido, o heteroarilo de 5-10 miembros opcionalmente sustituido; cada caso de R2 es, independientemente, halogeno, -OR9, -CF3, -CN, -NO2, -SO2R9, -SOR9, -C(O)R9, -CO2R9, -C(O)N(R9)2, -N3, -N2R9, -N(R9)2, alquilo C1-8 opcionalmente sustituido, alquenilo C2-8 opcionalmente sustituido, alquinilo C2-8 opcionalmente sustituido, heteroalquilo C1-8 opcionalmente sustituido, heteroalquenilo C2-8 opcionalmente sustituido, heteroalquinilo C2-8 opcionalmente sustituido, carbociclilo C3-10 opcionalmente sustituido, heterociclilo de 3-10 miembros opcionalmente sustituido, ariIo C6-10 opcionalmente sustituido o heteroarilo de 5-10 miembros opcionalmente sustituido; cada caso de R3 y R4 es, independientemente, aIquilo C1-8, opcionalmente sustituido, aIqueniIo C2-8 opcionalmente sustituido, aIquiniIo C2-8 opcionalmente sustituido, heteroalquilo C1-8 opcionalmente sustituido, heteroalquenilo C2-8 opcionalmente sustituido, heteroalquinilo C2-8 opcionalmente sustituido, carbociclilo C3-10 opcionalmente sustituido, heterociclilo de 3-10 miembros opcionalmente sustituido, ariIo C6-10 opcionalmente sustituido o heteroarilo de 5-10 miembros opcional mente sustituido; cada caso de R5, R6, R7, R8, R9, R10 y R14 es, independientemente, hidrogeno, -SO2R11, -SOR11, -C(O)R11, -CO2R11, -C(O)N(R11)2, -C(O)NH(R1 1), alquilo C1-8 opcionalmente sustituido, alquenilo C2-8 opcionalmente sustituido, aIquiniIo C2-8 opcionalmente sustituido, heteroalquilo C1-8 opcionalmente sustituido, heteroalquenilo C2-8 opcionalmente sustituido, heteroalquinilo C2-8 opcionalmente sustituido, carbociclilo C3-10 opcionalmente sustituido, heterociclilo de 3-10 miembros opcionalmente sustituido, ariIo C6-10 opcionalmente sustituido o heteroarilo de 5-10 miembros opcionalmente sustituido; cada caso de R11 es, independientemente, aIquiIo C1-8 opcionalmente sustituido, aIqueniIo C2-8 opcionalmente sustituido, aIquiniIo C2-8 opcionalmente sustituido, heteroalquilo C1-8 opcionalmente sustituido, h
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US4368608P | 2008-04-09 | 2008-04-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR072249A1 true AR072249A1 (es) | 2010-08-18 |
Family
ID=40912141
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP090101257A AR072249A1 (es) | 2008-04-09 | 2009-04-08 | Inhibidores de amida hidrolasa de acido graso. usos. metodos. |
Country Status (12)
Country | Link |
---|---|
US (2) | US8957049B2 (es) |
EP (1) | EP2282742A1 (es) |
JP (1) | JP5637982B2 (es) |
CN (1) | CN102046179B (es) |
AR (1) | AR072249A1 (es) |
AU (1) | AU2009233711B2 (es) |
CA (1) | CA2721060A1 (es) |
CL (1) | CL2009000870A1 (es) |
IL (1) | IL208536A0 (es) |
PE (1) | PE20091838A1 (es) |
TW (1) | TW201000107A (es) |
WO (1) | WO2009126691A1 (es) |
Families Citing this family (59)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JO3598B1 (ar) | 2006-10-10 | 2020-07-05 | Infinity Discovery Inc | الاحماض والاسترات البورونية كمثبطات اميد هيدروليز الحامض الدهني |
TW201000107A (en) | 2008-04-09 | 2010-01-01 | Infinity Pharmaceuticals Inc | Inhibitors of fatty acid amide hydrolase |
WO2010118155A1 (en) | 2009-04-07 | 2010-10-14 | Infinity Pharmaceuticals, Inc. | Inhibitors of fatty acid amide hydrolase |
WO2010118159A1 (en) | 2009-04-07 | 2010-10-14 | Infinity Pharmaceuticals, Inc. | Inhibitors of fatty acid amide hydrolase |
WO2010124113A1 (en) | 2009-04-23 | 2010-10-28 | Infinity Pharmaceuticals, Inc. | Anti-fatty acid amide hydrolase-2 antibodies and uses thereof |
US8927551B2 (en) | 2009-05-18 | 2015-01-06 | Infinity Pharmaceuticals, Inc. | Isoxazolines as inhibitors of fatty acid amide hydrolase |
US9149465B2 (en) | 2009-05-18 | 2015-10-06 | Infinity Pharmaceuticals, Inc. | Isoxazolines as inhibitors of fatty acid amide hydrolase |
CN102030770B (zh) * | 2009-09-25 | 2012-10-31 | 北京大学 | 一种芳香硼酸酯化合物的制备方法 |
MX2012004990A (es) | 2009-10-30 | 2012-06-12 | Janssen Pharmaceutica Nv | Deribados de imidazo [1,2-b] pirimideazina y su uso como inhibidores de la enzima fosfodiesterasa 10. |
WO2011085216A2 (en) | 2010-01-08 | 2011-07-14 | Ironwood Pharmaceuticals, Inc. | Use of faah inhibitors for treating parkinson's disease and restless legs syndrome |
CN102834401B (zh) | 2010-02-03 | 2016-08-24 | 无限药品股份有限公司 | 脂肪酸酰胺水解酶抑制剂 |
US8759535B2 (en) | 2010-02-18 | 2014-06-24 | High Point Pharmaceuticals, Llc | Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof |
AR080754A1 (es) | 2010-03-09 | 2012-05-09 | Janssen Pharmaceutica Nv | Derivados de imidazo (1,2-a) pirazina y su uso como inhibidores de pde10 |
US20130224151A1 (en) | 2010-03-31 | 2013-08-29 | United States Of America | Use of FAAH Inhibitors for Treating Abdominal, Visceral and Pelvic Pain |
EA201591390A1 (ru) | 2010-06-24 | 2016-06-30 | Джилид Сайэнс, Инк. | Пиразол[1,5-a]пиримидины для противовирусного лечения |
EP2624696B1 (en) | 2010-10-06 | 2016-12-21 | Glaxosmithkline LLC | Benzimidazole derivatives as pi3 kinase inhibitors |
WO2012087833A1 (en) | 2010-12-22 | 2012-06-28 | Abbott Laboratories | Hepatitis c inhibitors and uses thereof |
JP2012232924A (ja) * | 2011-04-28 | 2012-11-29 | Tosoh Corp | 新規なナフチルボロン酸化合物及びその製造法 |
BR112013033375B1 (pt) | 2011-06-27 | 2022-05-10 | Janssen Pharmaceutica N.V | Derivados de 1-aril-4-metil-[1,2,4]triazolo[4,3-a]quinoxa-lina, seu uso, composição farmacêutica que os compreende, processo de preparação dos mesmos, solução estéril e composto intermediário |
SI3689878T1 (sl) * | 2011-07-19 | 2021-12-31 | Merck Sharp & Dohme B.V. | 4-imidazopiridazin-1-il-benzamidi in 4-imidazotriazin-1-il-benzamidi kot Btk-zaviralci |
US9199975B2 (en) | 2011-09-30 | 2015-12-01 | Asana Biosciences, Llc | Biaryl imidazole derivatives for regulating CYP17 |
EP2794611B1 (en) | 2011-12-22 | 2017-10-11 | Gilead Sciences, Inc. | Pyrazolo[1,5-a]pyrimidines as antiviral agents |
CN106986869A (zh) | 2012-04-17 | 2017-07-28 | 吉利德科学公司 | 用于抗病毒治疗的化合物和方法 |
CN104411312B (zh) | 2012-06-26 | 2018-03-06 | 詹森药业有限公司 | 包括pde2抑制剂例如1‑芳基‑4‑甲基‑[1,2,4]***[4,3‑a]‑喹喔啉化合物和pde10抑制剂的用于在治疗神经病学障碍或代谢障碍中使用的组合 |
MX362197B (es) | 2012-07-09 | 2019-01-08 | Janssen Pharmaceutica Nv | Derivados de imidazo[1,2-b]piridazina e imidazo[1,2-a]pirazina como inhibidores de la fosfodiesterasa 10; y el uso de los mismos en el tratamiento de trastornos neurológicos, psiquiátricos y metabólicos. |
US9464098B2 (en) * | 2012-12-03 | 2016-10-11 | Hoffmann-La Roche Inc. | Substituted triazole boronic acid compounds |
CA2894399A1 (en) | 2012-12-06 | 2014-06-12 | Quanticel Pharmaceuticals, Inc. | Histone demethylase inhibitors |
WO2014127214A1 (en) | 2013-02-15 | 2014-08-21 | Kala Pharmaceuticals, Inc. | Therapeutic compounds and uses thereof |
US9688688B2 (en) | 2013-02-20 | 2017-06-27 | Kala Pharmaceuticals, Inc. | Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof |
AU2014219024B2 (en) | 2013-02-20 | 2018-04-05 | KALA BIO, Inc. | Therapeutic compounds and uses thereof |
EP2961746B1 (en) | 2013-02-28 | 2018-01-03 | Bristol-Myers Squibb Company | Phenylpyrazole derivatives as potent rock1 and rock2 inhibitors |
TW201444798A (zh) | 2013-02-28 | 2014-12-01 | 必治妥美雅史谷比公司 | 作爲強效rock1及rock2抑制劑之苯基吡唑衍生物 |
AU2014342042B2 (en) | 2013-11-01 | 2017-08-17 | KALA BIO, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
US9890173B2 (en) | 2013-11-01 | 2018-02-13 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
EP3134418A4 (en) * | 2014-04-23 | 2018-01-03 | The Research Foundation for The State University of New York | A rapid and efficient bioorthogonal ligation reaction and boron-containing heterocycles useful in conjuction therewith |
JP6615876B2 (ja) * | 2014-06-26 | 2019-12-04 | モナシュ ユニヴァーシティ | 酵素相互作用薬剤 |
EP3473630B1 (en) * | 2014-07-02 | 2021-01-13 | Xavier University Of Louisiana | Boron-based prodrug strategy for increased bioavailability and lower-dosage requirements for drug molecules containing at least one phenol (or aromatic hydroxyl) group |
WO2016089648A1 (en) | 2014-12-01 | 2016-06-09 | Vtv Therapeutics Llc | Bach 1 inhibitors in combination with nrf2 activators and pharmaceutical compositions thereof |
MA41562B1 (fr) | 2015-06-03 | 2019-05-31 | Bristol Myers Squibb Co | Agonistes d'apj 4-hydroxy-3-(heteroaryl)pyridine-2-one a utiliser dans le traitement de troubles cardio-vasculaires |
CN106800569B (zh) * | 2016-12-12 | 2019-04-16 | 上海中医药大学附属龙华医院 | Atg类似物及其制备方法和应用 |
JOP20190024A1 (ar) | 2016-08-26 | 2019-02-19 | Gilead Sciences Inc | مركبات بيروليزين بها استبدال واستخداماتها |
US10392399B2 (en) | 2016-09-08 | 2019-08-27 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
BR112019004463A2 (pt) | 2016-09-08 | 2019-05-28 | Kala Pharmaceuticals Inc | formas cristalinas de compostos terapêuticos, seus processos de obtenção e seus métodos de uso |
CA3036336A1 (en) | 2016-09-08 | 2018-03-15 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
WO2018090717A1 (zh) * | 2016-11-16 | 2018-05-24 | 上海中医药大学附属龙华医院 | Atg类似物及其制备方法和应用 |
EP3759109B1 (en) | 2018-02-26 | 2023-08-30 | Gilead Sciences, Inc. | Substituted pyrrolizine compounds as hbv replication inhibitors |
CN109180712B (zh) * | 2018-08-08 | 2020-12-25 | 南京医科大学 | 一类2-茨醇的芳基硼酸酯衍生物及其应用 |
CN109096043B (zh) * | 2018-08-24 | 2021-03-12 | 盐城师范学院 | 一种2,5-二溴碘苯的合成方法 |
DK3860998T3 (da) | 2018-10-05 | 2024-03-25 | Annapurna Bio Inc | Forbindelser og sammensætninger til behandlinger af tilstande, der er forbundet med APJ-receptoraktivitet |
TW202128675A (zh) | 2019-12-06 | 2021-08-01 | 美商維泰克斯製藥公司 | 作為鈉通道調節劑之經取代四氫呋喃 |
EP4097099A4 (en) | 2020-02-07 | 2023-09-27 | Gasherbrum Bio, Inc. | HETEROCYCLIC GLP-1 AGONISTS |
US11643394B2 (en) | 2020-04-30 | 2023-05-09 | Icahn School Of Medicine At Mount Sinai | Krüppel-like factor 15 (KLF15) small molecule agonists in kidney disease |
AU2021267373A1 (en) | 2020-05-06 | 2022-12-08 | Ajax Therapeutics, Inc. | 6-heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors |
CN112147273B (zh) * | 2020-11-02 | 2022-08-16 | 北京市理化分析测试中心 | 一种检测油品中微量酸的方法 |
US11827627B2 (en) | 2021-06-04 | 2023-11-28 | Vertex Pharmaceuticals Incorporated | N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamides as modulators of sodium channels |
KR102567789B1 (ko) * | 2021-06-08 | 2023-08-17 | 한국원자력의학원 | 신규한 벤조사이아졸 유도체 및 붕소 중성자 포획 요법에 있어서의 이의 용도 |
AU2022292554A1 (en) | 2021-06-14 | 2024-01-04 | Scorpion Therapeutics, Inc. | Urea derivatives which can be used to treat cancer |
WO2023086319A1 (en) | 2021-11-09 | 2023-05-19 | Ajax Therapeutics, Inc. | 6-he tero aryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors |
WO2023122778A1 (en) | 2021-12-22 | 2023-06-29 | Gossamer Bio Services, Inc. | Pyridazinone derivatives useful as t cell activators |
Family Cites Families (212)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4270537A (en) | 1979-11-19 | 1981-06-02 | Romaine Richard A | Automatic hypodermic syringe |
US4499082A (en) | 1983-12-05 | 1985-02-12 | E. I. Du Pont De Nemours And Company | α-Aminoboronic acid peptides |
US4596556A (en) | 1985-03-25 | 1986-06-24 | Bioject, Inc. | Hypodermic injection apparatus |
CA1268808A (en) | 1985-07-23 | 1990-05-08 | Alan G. Macdiarmid | High capacity polyaniline electrodes |
CH671400A5 (es) | 1986-12-17 | 1989-08-31 | Nii Prikladnych | |
CA1283827C (en) | 1986-12-18 | 1991-05-07 | Giorgio Cirelli | Appliance for injection of liquid formulations |
GB8704027D0 (en) | 1987-02-20 | 1987-03-25 | Owen Mumford Ltd | Syringe needle combination |
US4941880A (en) | 1987-06-19 | 1990-07-17 | Bioject, Inc. | Pre-filled ampule and non-invasive hypodermic injection device assembly |
US4790824A (en) | 1987-06-19 | 1988-12-13 | Bioject, Inc. | Non-invasive hypodermic injection device |
DE3807862A1 (de) | 1988-03-10 | 1989-09-21 | Merck Patent Gmbh | Smektische fluessigkristallphase |
US5273680A (en) | 1988-03-10 | 1993-12-28 | Merck Patent Gesellschaft Mit Beschrankter Haftung | Fluorinated oligophenyls and their use in liquid crystal materials |
US5339163A (en) | 1988-03-16 | 1994-08-16 | Canon Kabushiki Kaisha | Automatic exposure control device using plural image plane detection areas |
FR2638359A1 (fr) | 1988-11-03 | 1990-05-04 | Tino Dalto | Guide de seringue avec reglage de la profondeur de penetration de l'aiguille dans la peau |
GB8829296D0 (en) | 1988-12-15 | 1989-01-25 | Ici Plc | Anti-tumour compounds |
US5312335A (en) | 1989-11-09 | 1994-05-17 | Bioject Inc. | Needleless hypodermic injection device |
US5064413A (en) | 1989-11-09 | 1991-11-12 | Bioject, Inc. | Needleless hypodermic injection device |
DE59108963D1 (de) | 1990-02-01 | 1998-05-20 | Merck Patent Gmbh | Verfahren zur Umsetzung von fluorierten Aromaten mit Elektrophilen |
DE4014488A1 (de) | 1990-05-07 | 1991-11-14 | Merck Patent Gmbh | Dioxaborinane und fluessigkristallines medium |
US5190521A (en) | 1990-08-22 | 1993-03-02 | Tecnol Medical Products, Inc. | Apparatus and method for raising a skin wheal and anesthetizing skin |
US5527288A (en) | 1990-12-13 | 1996-06-18 | Elan Medical Technologies Limited | Intradermal drug delivery device and method for intradermal delivery of drugs |
EP0501268B1 (de) | 1991-02-25 | 1996-06-12 | F. Hoffmann-La Roche Ag | Flüssigkristalline Verbindungen mit endständigem 1-Alkinylrest |
AU2014892A (en) | 1991-04-30 | 1992-12-21 | Procter & Gamble Company, The | Liquid detergents with an aryl boronic acid |
GB2258232B (en) | 1991-07-31 | 1995-03-15 | Merck Patent Gmbh | Alkoxymethylene fluoroterphenyls and liquid crystalline medium |
GB9118204D0 (en) | 1991-08-23 | 1991-10-09 | Weston Terence E | Needle-less injector |
SE9102652D0 (sv) | 1991-09-13 | 1991-09-13 | Kabi Pharmacia Ab | Injection needle arrangement |
GB9300059D0 (en) | 1992-01-20 | 1993-03-03 | Zeneca Ltd | Quinazoline derivatives |
US5328483A (en) | 1992-02-27 | 1994-07-12 | Jacoby Richard M | Intradermal injection device with medication and needle guard |
CH683522A5 (de) | 1992-03-13 | 1994-03-31 | Hoffmann La Roche | Verfahren zur Herstellung von Diarylen. |
FR2688783A1 (fr) | 1992-03-23 | 1993-09-24 | Rhone Poulenc Chimie | Nouveaux borates d'onium ou de complexe organometallique amorceurs cationiques de polymerisation. |
FR2688790B1 (fr) | 1992-03-23 | 1994-05-13 | Rhone Poulenc Chimie | Compositions a base de polyorganosiloxanes a groupements fonctionnels reticulables et leur utilisation pour la realisation de revetements anti-adhesifs. |
US5541061A (en) | 1992-04-29 | 1996-07-30 | Affymax Technologies N.V. | Methods for screening factorial chemical libraries |
PL167141B1 (pl) | 1992-05-12 | 1995-07-31 | Wojskowa Akad Tech | Sposób otrzymywania związków ciekłokrystalicznych zawierających pierścień 1,3-dioksa- -2-boranu |
JP3255965B2 (ja) | 1992-05-26 | 2002-02-12 | 昭和シェル石油株式会社 | 反強誘電性液晶化合物 |
DE4220065A1 (de) | 1992-06-19 | 1993-12-23 | Merck Patent Gmbh | Verfahren zur Herstellung von Pyrimidin-Derivaten |
US5383851A (en) | 1992-07-24 | 1995-01-24 | Bioject Inc. | Needleless hypodermic injection device |
GB9220189D0 (en) | 1992-09-24 | 1992-11-04 | Central Research Lab Ltd | Dioxane derivatives |
US5569189A (en) | 1992-09-28 | 1996-10-29 | Equidyne Systems, Inc. | hypodermic jet injector |
GB9220750D0 (en) | 1992-10-02 | 1992-11-18 | Merck Patent Gmbh | Liquid crystalline material forming ananisotropic |
DE4236103A1 (de) | 1992-10-26 | 1994-04-28 | Hoechst Ag | Verfahren zur Kreuzkupplung von aromatischen Boronsäuren mit aromatischen Halogenverbindungen oder Perfluoralkylsulfonaten |
US5334144A (en) | 1992-10-30 | 1994-08-02 | Becton, Dickinson And Company | Single use disposable needleless injector |
TW240217B (es) | 1992-12-30 | 1995-02-11 | Glaxo Group Ltd | |
US5576220A (en) | 1993-02-19 | 1996-11-19 | Arris Pharmaceutical Corporation | Thin film HPMP matrix systems and methods for constructing and displaying ligands |
FR2702485B1 (fr) | 1993-03-10 | 1995-04-14 | Rhone Poulenc Chimie | Compositions à base de polyorganosiloxanes réticulables par voie cationique et leur utilisation dans le domaine de l'antiadhérence papier, de la protection des fibres optiques et des circuits imprimés. |
US5563127A (en) | 1993-03-24 | 1996-10-08 | The Dupont Merck Pharmaceutical Company | Boronic acid and ester inhibitors of thrombin |
US5417885A (en) | 1993-08-03 | 1995-05-23 | Showa Shell Sekiyu Kabushiki Kaisha | Antiferroelectric liquid crystal compound |
US5431842A (en) | 1993-11-05 | 1995-07-11 | The Procter & Gamble Company | Liquid detergents with ortho-substituted phenylboronic acids for inhibition of proteolytic enzyme |
JPH07145174A (ja) | 1993-11-22 | 1995-06-06 | Takeda Chem Ind Ltd | ジオキサボリナン系化合物、それらの製造方法、該化合物を含む液晶組成物および該組成物を用いた液晶光変調装置 |
JPH07165717A (ja) | 1993-12-16 | 1995-06-27 | Sumitomo Chem Co Ltd | 複素環化合物およびその製造法 |
JPH07206715A (ja) | 1994-01-21 | 1995-08-08 | Sumitomo Chem Co Ltd | 複素環化合物の製造法 |
DE19502178A1 (de) | 1994-01-27 | 1995-08-03 | Hoechst Ag | Thiadiazolderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Vorprodukte zur Herstellung von Flüssigkristallen |
WO1995024176A1 (en) | 1994-03-07 | 1995-09-14 | Bioject, Inc. | Ampule filling device |
US5466220A (en) | 1994-03-08 | 1995-11-14 | Bioject, Inc. | Drug vial mixing and transfer device |
US5643893A (en) | 1994-06-22 | 1997-07-01 | Macronex, Inc. | N-substituted-(Dihydroxyboryl)alkyl purine, indole and pyrimidine derivatives, useful as inhibitors of inflammatory cytokines |
JP3702426B2 (ja) | 1994-08-03 | 2005-10-05 | 関東化学株式会社 | トリフルオロメチルベンゼン誘導体および液晶組成物 |
FR2724660B1 (fr) | 1994-09-16 | 1997-01-31 | Rhone Poulenc Chimie | Amorceurs de reticulation, par voie cationique, de polymeres a groupements organofonctionnels, compositions a base de polyorganosiloxanes reticulables et contenant ces amorceurs et application desdites compositions en antiadherence |
JPH0892137A (ja) | 1994-09-26 | 1996-04-09 | Sumitomo Chem Co Ltd | 芳香族エステル化合物、その製造法および用途 |
FR2727416A1 (fr) | 1994-11-24 | 1996-05-31 | Rhone Poulenc Chimie | Nouveaux amorceurs cationiques thermoactivables, de polymerisation et/ou de reticulation et compositions monomeres et/ou polymeres fonctionnels les mettant en oeuvre |
DE4445224B4 (de) | 1994-12-17 | 2014-03-27 | Merck Patent Gmbh | Benzolderivate |
US5599302A (en) | 1995-01-09 | 1997-02-04 | Medi-Ject Corporation | Medical injection system and method, gas spring thereof and launching device using gas spring |
US5730723A (en) | 1995-10-10 | 1998-03-24 | Visionary Medical Products Corporation, Inc. | Gas pressured needle-less injection device and method |
US6271015B1 (en) | 1995-06-12 | 2001-08-07 | The Scripps Research Institute | Fatty-acid amide hydrolase |
JP3783246B2 (ja) | 1995-07-18 | 2006-06-07 | 大日本インキ化学工業株式会社 | p−テルフェニル誘導体 |
EP0755918B1 (de) | 1995-07-28 | 2000-09-06 | Rolic AG | Photovernetzbare flüssigkristalline 1,2-Phenylen-Derivate |
WO1997006124A1 (fr) | 1995-08-09 | 1997-02-20 | Chisso Corporation | Derives du cyclohexane et compositions a cristaux liquides |
US5893397A (en) | 1996-01-12 | 1999-04-13 | Bioject Inc. | Medication vial/syringe liquid-transfer apparatus |
FR2745288B1 (fr) | 1996-02-27 | 1998-04-17 | Adir | Nouveaux derives de l'acide boronique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
GB9605334D0 (en) | 1996-03-13 | 1996-05-15 | British Nuclear Fuels Plc | Biodecontamination reactor |
JP3555325B2 (ja) | 1996-04-12 | 2004-08-18 | チッソ株式会社 | ビアリール誘導体の製造方法 |
US5998673A (en) | 1996-06-03 | 1999-12-07 | American Cyanamid Company | 1, 4-diaryl-2-fluoro-2-butene insecticidal and acaricidal agents |
US5892131A (en) | 1997-05-29 | 1999-04-06 | American Cyanamid Company | Process for the preparation of pesticidal fluoroolefin compounds |
US5849958A (en) | 1997-03-17 | 1998-12-15 | American Cyanamid Company | 1,4,diaryl-2-fluoro-2-butene insecticidal and acaricidal agents |
ZA974582B (en) | 1996-06-03 | 1998-11-26 | American Cyanamid Co | Process and intermediate compounds for the preparation of pesticidal fluoroolefin compounds |
BG63255B1 (bg) | 1996-06-03 | 2001-07-31 | American Cyanamid Company | 1,4-диарил-2-флуоро-2-бутенови инсектицидни и акарицидни средства |
CA2206192A1 (en) | 1996-06-13 | 1997-12-13 | F. Hoffmann-La Roche Ag | Modulation of lc132 (opioid-like) receptor function |
US5856537A (en) | 1996-06-26 | 1999-01-05 | The Scripps Research Institute | Inhibitors of oleamide hydrolase |
JPH1025261A (ja) | 1996-07-09 | 1998-01-27 | Chisso Corp | フェノール誘導体の製造方法 |
DK0933346T3 (da) | 1996-07-31 | 2004-03-29 | Shionogi & Co | Nye p-terphenylforbindelser |
JP3899557B2 (ja) | 1996-08-21 | 2007-03-28 | 大日本インキ化学工業株式会社 | フルオロビフェニル誘導体 |
FR2752582B1 (fr) | 1996-08-21 | 2003-06-13 | Rhone Poulenc Chimie | Compositions a base de polyorganosiloxanes a groupements fonctionnels reticulables et leur utilisation pour la realisation de revetements anti-adherents |
JP4526605B2 (ja) | 1996-08-28 | 2010-08-18 | チッソ株式会社 | ラテラルハロゲン置換基を有する4環化合物および液晶組成物 |
US6177440B1 (en) | 1996-10-30 | 2001-01-23 | Eli Lilly And Company | Substituted tricyclics |
US5925672A (en) | 1996-12-06 | 1999-07-20 | Neurosciences Research Foundation, Inc. | Methods of treating mental diseases, inflammation and pain |
FR2757530A1 (fr) | 1996-12-24 | 1998-06-26 | Rhodia Chimie Sa | Utilisation pour la stereophotolithographie - d'une composition liquide photoreticulable par voie cationique comprenant un photoamorceur du type sels d'onium ou de complexes organometalliques |
FR2757870B1 (fr) | 1996-12-30 | 1999-03-26 | Rhodia Chimie Sa | Utilisation de compositions silicones reticulables par voie cationique sous uv et d'un photoamorceur du type borate d'onium, pour le revetements de joints plats, notamment de joints de culasse |
FR2758329B1 (fr) | 1997-01-16 | 1999-02-12 | Synthelabo | Derives d'imidazole-4-butane boronique, leur preparation et leur utilisation en therapeutique |
FR2758560B1 (fr) | 1997-01-20 | 2000-02-04 | Adir | Nouveaux derives d'acides aminophenylboronique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
FR2758723B1 (fr) | 1997-01-28 | 1999-04-23 | Sanofi Sa | Utilisation des antagonistes des recepteurs aux cannabinoides centraux pour la preparation de medicaments |
WO1998035924A1 (fr) | 1997-02-13 | 1998-08-20 | Chisso Corporation | Composes de cristaux liquides de structure bicyclo [1.1.1] pentane, composition pour cristaux liquides et elements d'affichages a cristaux liquides |
DE19710614A1 (de) | 1997-03-14 | 1998-09-17 | Hoechst Ag | (1,2,4)-Thiadiazolderivate, Verfahren zu ihrer Herstellung und ihre Verwendung |
US5993412A (en) | 1997-05-19 | 1999-11-30 | Bioject, Inc. | Injection apparatus |
AU8140898A (en) | 1997-06-13 | 1998-12-30 | Northwestern University | Inhibitors of beta-lactamases and uses therefor |
IT1298087B1 (it) | 1998-01-08 | 1999-12-20 | Fiderm S R L | Dispositivo per il controllo della profondita' di penetrazione di un ago, in particolare applicabile ad una siringa per iniezioni |
DE19909761A1 (de) | 1998-04-17 | 1999-10-21 | Merck Patent Gmbh | Benzofuran- und Benzodifuran-Derivate |
DZ2769A1 (fr) | 1998-04-17 | 2003-12-01 | Lilly Co Eli | Composés tricycliques substitués. |
JP2000001463A (ja) | 1998-06-12 | 2000-01-07 | Dainippon Ink & Chem Inc | 4−シアノベンゼン誘導体の製造方法 |
GB9814450D0 (en) | 1998-07-04 | 1998-09-02 | Sharp Kk | Novel compounds |
GB2339778A (en) | 1998-07-17 | 2000-02-09 | Secr Defence | Terphenyl Liquid Crystals |
WO2000020466A1 (de) | 1998-10-01 | 2000-04-13 | Targor Gmbh | Katalysatorsystem |
DE19857765A1 (de) * | 1998-12-15 | 2000-06-21 | Clariant Gmbh | Verfahren zur Herstellung von para-Oxadiazolyl-phenyl-boronsäuren |
DE19858594A1 (de) | 1998-12-18 | 2000-06-21 | Merck Patent Gmbh | Verfahren zur Herstellung von Cyanbenzolboronsäuren |
WO2000037476A1 (de) | 1998-12-19 | 2000-06-29 | Basell Polyolefine Gmbh | Verfahren zur herstellung von mono- oder di-organo-boranen |
MXPA01007099A (es) * | 1999-01-13 | 2002-03-27 | Univ New York State Res Found | Metodo novedoso para disenar inhibidores de la proteina cinasa. |
JP4507294B2 (ja) | 1999-05-27 | 2010-07-21 | チッソ株式会社 | ビアリール誘導体の製造方法 |
JP2003509507A (ja) | 1999-09-21 | 2003-03-11 | キネティック リミテッド | 液晶化合物 |
US6309406B1 (en) | 1999-11-24 | 2001-10-30 | Hamit-Darwin-Fresh, Inc. | Apparatus and method for inducing epileptic seizures in test animals for anticonvulsant drug screening |
NZ519183A (en) * | 1999-12-03 | 2005-02-25 | Ono Pharmaceutical Co | Triazaspiro[5.5]undecane derivatives and pharmaceutical compositions comprising thereof, as an active ingredient |
US20030096854A1 (en) | 2002-06-12 | 2003-05-22 | Ho-Shen Lin | Substituted tricyclics |
FR2805273B1 (fr) | 2000-02-18 | 2006-08-11 | Rhodia Chimie Sa | Traitement de surface de materiau plastique avec une composition a fonctions reactives polymerisable et/ou reticulable |
DE10009714A1 (de) | 2000-03-01 | 2001-09-06 | Targor Gmbh | Verfahren zur Herstellung von Mono- oder Di-organo-boranen |
GB2362882A (en) | 2000-06-02 | 2001-12-05 | Sharp Kk | Liquid crystalline optionally laterally fluorinated terphenyl with chiral 3,4-di[(un)saturated-alkoxy]butoxy or 1,4-di[(un)saturated-alkoxy]but-2-oxy terminus |
CA2419238A1 (en) | 2000-08-16 | 2002-02-21 | University Of Alberta | Non-pressurized methods for the preparation of conjugated solid supports for boronic acids |
ATE368653T1 (de) * | 2000-08-23 | 2007-08-15 | Lilly Co Eli | Oxazolylaryloxyessigsäure derivate und ihre verwendung als ppar agonisten |
US6927216B2 (en) | 2000-10-03 | 2005-08-09 | Bristol-Myers Squibb Pharma Company | Cyclic sulfonyl compounds as inhibitors of metalloproteases |
DE60140559D1 (de) | 2000-10-05 | 2009-12-31 | Millenium Pharmaceuticals Inc | 32144, eine humane fettsäureamid-hydrolase und deren verwendungen |
GB0100110D0 (en) | 2001-01-04 | 2001-02-14 | Univ Leeds | Modulation of calcium channel activity |
US20040235792A1 (en) * | 2001-01-20 | 2004-11-25 | Deadman John J | Serine protease inhibitors compromising a hydrogen-bond acceptor |
JP4721027B2 (ja) | 2001-03-29 | 2011-07-13 | Dic株式会社 | フェニルピリミジン誘導体の製造方法 |
US20030022864A1 (en) | 2001-04-24 | 2003-01-30 | Ishaq Khalid S. | 9-[(5-dihydroxyboryl)-pentyl] purines, useful as an inhibitor of inflammatory cytokines |
US6617125B2 (en) | 2001-06-29 | 2003-09-09 | Perkinelmer Life Sciences, Inc. | Compositions for enhanced catalyzed reporter deposition |
US6858592B2 (en) | 2001-06-29 | 2005-02-22 | Genzyme Corporation | Aryl boronic acids for treating obesity |
DE60205824T2 (de) | 2001-07-09 | 2006-05-18 | Merck Patent Gmbh | Thienothiophenderivate |
WO2003033002A1 (fr) * | 2001-10-11 | 2003-04-24 | Ono Pharmaceutical Co | Inhibiteurs de l'augmentation de la concentration du calcium intracellulaire |
CA2462348A1 (en) | 2001-10-12 | 2003-04-24 | Dow Global Technologies Inc. | Metal complex compositions and their use as catalysts to produce polydienes |
ATE360054T1 (de) | 2001-11-07 | 2007-05-15 | Merck Patent Gmbh | Flüssigkristalline verbindung, flüssigkristallines medium und flüssigkristallanzeige |
GB0126844D0 (en) | 2001-11-08 | 2002-01-02 | Qinetiq Ltd | Novel compounds |
EP2769715A3 (en) | 2001-11-26 | 2014-09-17 | Trustees Of Tufts College | Methods for treating autoimmune disorders, and reagents related thereto |
KR20040077660A (ko) * | 2001-12-12 | 2004-09-06 | 가부시끼가이샤 도꾸야마 | 유기 일렉트로루미네선스 소자 재료 |
DE10201764A1 (de) | 2002-01-18 | 2003-07-31 | Bayer Cropscience Ag | Substituierte 4-Aminopyridin-Derivate |
WO2003064484A1 (en) | 2002-01-28 | 2003-08-07 | Dow Global Technologies Inc. | Metal complex compositions based on cobalt and their use as polymerization catalyst for olefins and dienes |
DE10206759A1 (de) | 2002-02-19 | 2003-08-28 | Dragoco Gerberding Co Ag | Synergistische Mischungen von 1,2-Alkandiolen |
DE10211597A1 (de) | 2002-03-15 | 2003-10-02 | Merck Patent Gmbh | Verfahren zur Herstellung von Ringverbindungen |
AU2003223930A1 (en) | 2002-06-14 | 2003-12-31 | Novo Nordisk A/S | Pharmaceutical use of boronic acids and esters thereof |
NZ537206A (en) | 2002-06-27 | 2007-06-29 | Astellas Pharma Inc | Aminoalcohol derivatives |
EP1388538B1 (en) | 2002-07-09 | 2010-09-01 | Merck Patent GmbH | Polymerisation Initiator |
US20040115475A1 (en) | 2002-08-14 | 2004-06-17 | Matsushita Electric Industrial Co., Ltd. | Aromatic methylidene compound, methylstyrul compound for producing the same, production electroluminescent element |
EP1576127A4 (en) | 2002-11-14 | 2006-10-25 | Scripps Research Inst | CRYSTAL FORM OF FATTY ACID AMINE HYDROLASE (FAAH) |
CN100509792C (zh) | 2002-11-27 | 2009-07-08 | 默克专利股份有限公司 | 四氢吡喃衍生物 |
US6924269B2 (en) | 2002-12-04 | 2005-08-02 | Vdf Futureceuticals, Inc. | Enzyme inhibitors and methods therefor |
US7390806B2 (en) | 2002-12-18 | 2008-06-24 | Anacor Pharmaceuticals, Inc. | Antibiotics containing borinic acid complexes and methods of use |
US7456169B2 (en) * | 2003-02-27 | 2008-11-25 | Abbott Laboratories Inc. | Heterocyclic kinase inhibitors |
JP4787150B2 (ja) | 2003-03-06 | 2011-10-05 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | Jnk阻害剤 |
WO2004080989A1 (ja) | 2003-03-10 | 2004-09-23 | Sumitomo Chemical Company Limited | フラン化合物の製造方法 |
WO2004081008A1 (en) * | 2003-03-14 | 2004-09-23 | Astrazeneca Ab | Novel fused triazolones and the uses thereof |
JP2004292766A (ja) * | 2003-03-28 | 2004-10-21 | Tokuyama Corp | 有機エレクトロルミネッセンス素子材料 |
DE10325438A1 (de) | 2003-05-21 | 2004-12-09 | Bayer Cropscience Ag | Difluormethylbenzanilide |
EP2492264A3 (en) | 2003-06-03 | 2012-12-19 | Rib-X Pharmaceuticals, Inc. | Biaryl Heterocyclic Compounds And Methods Of Making And Using The Same |
CA2528587A1 (en) | 2003-06-10 | 2005-01-20 | Fulcrum Pharmaceuticals, Inc. | .beta.-lactamase inhibitors and methods of use thereof |
AU2004262524C1 (en) | 2003-06-16 | 2010-08-19 | Anacor Pharmaceuticals, Inc. | Hydrolytically-resistant boron-containing therapeutics and methods of use |
DE10337497A1 (de) | 2003-08-14 | 2005-03-10 | Bayer Cropscience Ag | 4-Biphenylsubstituierte-Pyrazolidin-3,5-dion-Derivate |
WO2005037227A2 (en) | 2003-10-16 | 2005-04-28 | Microbia, Inc. | Selective cox-2 inhibitors |
JP2007512244A (ja) | 2003-10-31 | 2007-05-17 | フルクラム・ファーマシューティカルズ・インコーポレーテッド | コロナウイルスプロテアーゼの阻害剤およびその使用方法 |
EP1682499B1 (en) | 2003-11-10 | 2007-08-08 | Microbia, Inc. | 4-biarylyl-1-phenylazetidin-2-ones |
US20070010559A1 (en) | 2003-11-25 | 2007-01-11 | Novo Nordisk A/S | Indole derivatives for use as chemical uncoupler |
JP4491666B2 (ja) | 2003-12-02 | 2010-06-30 | 東ソー株式会社 | フルオレン骨格を有するアリールアミン誘導体の製造方法とその合成中間体 |
GB2410745B (en) | 2004-02-06 | 2007-07-25 | Merck Patent Gmbh | Cholestanyl derivatives |
EP1717230B1 (en) | 2004-02-13 | 2014-08-06 | Msd K.K. | Fused-ring 4-oxopyrimidine derivative |
GB0403744D0 (en) | 2004-02-20 | 2004-03-24 | Astrazeneca Ab | Chemical process |
DE102004041532A1 (de) | 2004-08-27 | 2006-03-02 | Bayer Cropscience Ag | Biphenylthiazolcarboxamide |
DE102004041530A1 (de) | 2004-08-27 | 2006-03-02 | Bayer Cropscience Ag | Biphenylthiazolcarboxamide |
US20100286211A1 (en) * | 2004-10-08 | 2010-11-11 | Biswajit Das | Oxazolidinone derivatives as antimicrobials |
WO2006050236A2 (en) | 2004-11-01 | 2006-05-11 | Nuada, Llc | Compounds and methods of use thereof |
WO2006050054A2 (en) | 2004-11-01 | 2006-05-11 | Nuada, Llc | Compounds and methods of use thereof |
JP2008518923A (ja) | 2004-11-01 | 2008-06-05 | ヌアダ,リミテッド・ライアビリティ・カンパニー | 化合物およびその使用方法 |
WO2006053250A2 (en) | 2004-11-12 | 2006-05-18 | Trustees Of Tufts College | Lipase inhibitors |
DE102005023834A1 (de) | 2004-11-20 | 2006-05-24 | Bayer Healthcare Ag | Substituierte[(Phenylethanoyl)amino]benzamide |
WO2006060625A2 (en) | 2004-12-02 | 2006-06-08 | Displaytech, Inc. | Liquid crystal compositions comprising an organogermanium compound and methods for using the same |
US7553496B2 (en) | 2004-12-21 | 2009-06-30 | University Of Kentucky Research Foundation | VEGF-A as an inhibitor of angiogenesis and methods of using same |
JP2008526980A (ja) | 2005-01-14 | 2008-07-24 | ジェネラブズ テクノロジーズ インコーポレーティッド | ウイルス感染症を治療するためのインドール誘導体 |
US20090005321A1 (en) | 2005-02-09 | 2009-01-01 | Microbia, Inc. | Phenylazetidinone Derivatives |
PT3424932T (pt) | 2005-02-16 | 2021-05-19 | Anacor Pharmaceuticals Inc | Boronoftalidas para utilização terapêutica |
GB2436766B (en) | 2005-02-22 | 2012-02-08 | Sumation Co Ltd | High bandgap arylene polymers |
EP1863513A2 (en) | 2005-03-11 | 2007-12-12 | The University of North Carolina at Chapel Hill | Potent and specific immunoproteasome inhibitors |
GB2424881B (en) | 2005-04-07 | 2010-11-24 | Merck Patent Gmbh | Halophenyl derivatives of bisalkylfluorene |
JP4792796B2 (ja) | 2005-04-08 | 2011-10-12 | 東ソー株式会社 | 2,3−ジハロビフェニレン誘導体、その前駆化合物及び製造方法 |
WO2006122186A2 (en) | 2005-05-10 | 2006-11-16 | Microbia, Inc. | 1,4-diphenyl-3-hydroxyalkyl-2-azetidinone derivatives for treating hypercholestrolemia |
TW200740752A (en) | 2005-05-13 | 2007-11-01 | Microbia Inc | 4-Biarylyl-1-phenylazetidin-2-ones |
US7674876B2 (en) | 2005-05-25 | 2010-03-09 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Synthesis of novel monomers containing the trifluorovinylidene group and the cyanato group and polymers thereof |
JP2008546651A (ja) | 2005-06-14 | 2008-12-25 | メルク フロスト カナダ リミテツド | モノアミンオキシダーゼa及びbの可逆的阻害剤 |
KR100659088B1 (ko) | 2005-07-15 | 2006-12-21 | 삼성에스디아이 주식회사 | 디플루오로피리딘계 화합물 및 이를 이용한 유기 발광 소자 |
TW200740823A (en) * | 2005-08-01 | 2007-11-01 | Ihara Chemical Ind Co | Oxadiazole-substituted Sym-triindole derivative and organic el element employing the same |
DE102005037925A1 (de) | 2005-08-11 | 2007-02-15 | Merck Patent Gmbh | Hydro-cyclopenta[a]naphthaline |
US7589239B2 (en) * | 2005-09-02 | 2009-09-15 | Auspex Pharmaceuticals | Therapeutic agents for the treatment of cancer, metabolic diseases and skin disorders |
US7999137B2 (en) | 2005-09-13 | 2011-08-16 | Bayer Cropscience Ag | Pesticide bi-phenyl-amidine derivatives |
CA2630460C (en) * | 2005-12-01 | 2013-01-08 | F. Hoffmann-La Roche Ag | Heteroaryl substituted piperidine derivatives as l-cpt1 inhibitors |
KR101408026B1 (ko) | 2005-12-02 | 2014-06-20 | 사켐,인코포레이티드 | 음이온-교환 치환 크로마토그래피 공정 및 음이온-교환치환 크로마토그래피 공정에서 디스플레이서 화합물들로서사용하기 위한 음이온성 유기 화합물들 |
RU2008131324A (ru) * | 2005-12-30 | 2010-02-10 | Анакор Фармасьютикалз, Инк. (Us) | Борсодержащие малые молекулы |
WO2007076875A2 (en) * | 2006-01-06 | 2007-07-12 | Aarhus Universitet | Compounds acting on the serotonin transporter |
GB0602046D0 (en) * | 2006-02-01 | 2006-03-15 | Smithkline Beecham Corp | Compounds |
ES2728455T3 (es) * | 2006-02-16 | 2019-10-24 | Anacor Pharmaceuticals Inc | Moléculas pequeñas que contienen boro como agentes antiinflamatorios |
AR059898A1 (es) | 2006-03-15 | 2008-05-07 | Janssen Pharmaceutica Nv | Derivados de 3-ciano-piridona 1,4-disustituida y su uso como moduladores alostericos de los receptores mglur2 |
DE102007009944B4 (de) | 2006-03-15 | 2016-04-28 | Merck Patent Gmbh | Flüssigkristallines Medium und seine Verwendung |
CA2584745A1 (en) | 2006-04-13 | 2007-10-13 | Aegera Therapeutics Inc. | Use of imidazo(2,1-b) -1,3,4-thiadiazole-2-sulfonamide compounds to treat neuropathic pain |
JP5145753B2 (ja) | 2006-04-20 | 2013-02-20 | Jnc株式会社 | フルオロイソプロピル基を側鎖として有する化合物およびこれを用いた液晶組成物 |
AU2007257689A1 (en) * | 2006-06-12 | 2007-12-21 | Anacor Pharmaceuticals, Inc. | Compounds for the treatment of periodontal disease |
US7838542B2 (en) * | 2006-06-29 | 2010-11-23 | Kinex Pharmaceuticals, Llc | Bicyclic compositions and methods for modulating a kinase cascade |
EP2046769A2 (en) | 2006-07-27 | 2009-04-15 | Cv Therapeutics, Inc. | Aldh-2 inhibitors in the treatment of addiction |
US8034940B2 (en) * | 2006-08-09 | 2011-10-11 | Bristol-Myers Squibb Company | Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof |
US8236783B2 (en) * | 2006-08-15 | 2012-08-07 | Duke University | ROS-sensitive iron chelators and methods of using the same |
WO2008019743A1 (de) | 2006-08-16 | 2008-02-21 | Merck Patent Gmbh | Cyclohexen-verbindungen für flüssigkristalline mischungen |
EP1900792B1 (de) | 2006-09-13 | 2010-08-04 | Merck Patent GmbH | Fluorphenyl-Verbindungen für flüssigkristalline Mischungen |
WO2008039829A2 (en) | 2006-09-26 | 2008-04-03 | Ironwood Pharmaceuticals, Inc. | Diphenylheterocycle cholesterol absorption inhibitors |
JO3598B1 (ar) * | 2006-10-10 | 2020-07-05 | Infinity Discovery Inc | الاحماض والاسترات البورونية كمثبطات اميد هيدروليز الحامض الدهني |
MX2009004233A (es) | 2006-10-18 | 2009-08-12 | Pfizer Prod Inc | Compuestos de biaril eter urea. |
CN101616883B (zh) | 2007-01-24 | 2014-06-18 | Jnc株式会社 | 液晶性化合物、液晶组成物以及液晶显示元件 |
US7951433B2 (en) | 2007-02-28 | 2011-05-31 | Chisso Corporation | Five-ring liquid crystal compound having CF2O bonding group, liquid crystal composition, and liquid crystal display device |
GB2460784A (en) * | 2007-03-07 | 2009-12-16 | Dong A Pharmtech Co Ltd | Novel phenylpropionic acid derivatives as peroxisome proliferator-activated gamma receptor modulators,method of the same,and pharmaceutical composition |
TW200900065A (en) | 2007-03-07 | 2009-01-01 | Janssen Pharmaceutica Nv | 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives |
US7741347B2 (en) * | 2007-05-17 | 2010-06-22 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
WO2009011904A1 (en) | 2007-07-19 | 2009-01-22 | Renovis, Inc. | Compounds useful as faah modulators and uses thereof |
TW201000107A (en) | 2008-04-09 | 2010-01-01 | Infinity Pharmaceuticals Inc | Inhibitors of fatty acid amide hydrolase |
CN102015585B (zh) | 2008-05-08 | 2013-06-19 | 住友化学株式会社 | 不饱和有机化合物的制造方法 |
DE102008023801A1 (de) | 2008-05-15 | 2009-11-19 | Bayer Schering Pharma Aktiengesellschaft | Substituierte Imidazo- und Triazolopyrimidine, Imidazo- und Pyrazolopyrazine und Imidazotriazine |
-
2009
- 2009-04-08 TW TW098111651A patent/TW201000107A/zh unknown
- 2009-04-08 EP EP09729529A patent/EP2282742A1/en not_active Withdrawn
- 2009-04-08 WO PCT/US2009/039872 patent/WO2009126691A1/en active Application Filing
- 2009-04-08 JP JP2011504146A patent/JP5637982B2/ja not_active Expired - Fee Related
- 2009-04-08 AU AU2009233711A patent/AU2009233711B2/en not_active Ceased
- 2009-04-08 AR ARP090101257A patent/AR072249A1/es unknown
- 2009-04-08 PE PE2009000498A patent/PE20091838A1/es not_active Application Discontinuation
- 2009-04-08 CA CA2721060A patent/CA2721060A1/en not_active Abandoned
- 2009-04-08 CN CN200980119527.3A patent/CN102046179B/zh not_active Expired - Fee Related
- 2009-04-09 CL CL2009000870A patent/CL2009000870A1/es unknown
-
2010
- 2010-10-07 IL IL208536A patent/IL208536A0/en unknown
- 2010-10-08 US US12/901,421 patent/US8957049B2/en not_active Expired - Fee Related
-
2015
- 2015-01-16 US US14/599,192 patent/US20150368278A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
CN102046179B (zh) | 2015-01-14 |
AU2009233711A1 (en) | 2009-10-15 |
JP2011516564A (ja) | 2011-05-26 |
US20110172186A1 (en) | 2011-07-14 |
WO2009126691A1 (en) | 2009-10-15 |
CA2721060A1 (en) | 2009-10-15 |
AU2009233711B2 (en) | 2015-02-12 |
US8957049B2 (en) | 2015-02-17 |
CN102046179A (zh) | 2011-05-04 |
JP5637982B2 (ja) | 2014-12-10 |
US20150368278A1 (en) | 2015-12-24 |
IL208536A0 (en) | 2010-12-30 |
TW201000107A (en) | 2010-01-01 |
CL2009000870A1 (es) | 2010-06-25 |
PE20091838A1 (es) | 2009-12-18 |
EP2282742A1 (en) | 2011-02-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR072249A1 (es) | Inhibidores de amida hidrolasa de acido graso. usos. metodos. | |
AR083199A1 (es) | Compuestos de n-heteroarilo con unidad de puente ciclico | |
AR086983A1 (es) | Derivados de azetidinil fenil, piridil o pirazinil carboxamida como inhibidores de jak | |
BR112013020539A2 (pt) | sais de diamínio fenotiazina e seu uso | |
CA2972014A1 (en) | Fused pyrimidine compounds for the treatment of hiv | |
EA201201031A1 (ru) | Ингибиторы вируса гепатита с | |
AR083367A1 (es) | Compuestos de tipo quinazolinona como antagonistas de crth | |
SI3024819T1 (en) | Glyoxamide-substituted pyrrolamide derivatives and their use as medicines for the treatment of hepatitis B | |
BR112015015812A2 (pt) | derivados de pirimidina fundidos a pirido ou pirrolo como inibidores de autotaxina para tratamento de dor | |
EA201490491A1 (ru) | Производные 2-амино-4-(пиридин-2-ил)-5,6-дигидро-4h-1,3-оксазинов и их использование в качестве ингибиторов bace-1 и/или bace-2 | |
RU2014129742A (ru) | Производные бензолсульфонамида в качестве модуляторов rorc | |
JP2011132222A5 (es) | ||
BR122019017036B8 (pt) | compostos de arilamidas substituídas por tetrazol, usos dos referidos compostos e composição farmacêutica | |
AR063165A1 (es) | Derivados de acido boronico como inhibidores de amidihidrolasa de acidos grasos. composiciones farmaceuticas. | |
AR082152A1 (es) | Derivados de n-(metilsulfonil)benzamida, composiciones farmaceuticas que los comprenden y su uso en la preparacion de medicamentos para el tratamiento de enfermedades mediadas por la inhibicion de nav1.7 | |
AR094262A1 (es) | Compuestos antivirales para el tratamiento de la hepatitis c | |
MA37712A2 (fr) | Inhibiteurs macrocycliques de virus flaviviridae | |
RS54288B1 (en) | SUBSTITUTED TRIAZOLOPYRIDINES AND THEIR USE AS TTK INHIBITORS | |
AR062050A1 (es) | Derivados de amina utiles como agentes anti-cancerigenos | |
AR078786A1 (es) | Derivados de la cromenona | |
AR064199A1 (es) | Derivados de bencimidazol y benzotriazol como inhibidores de transcriptasa inversa no nucleosidicos composiciones farmaceuticas que los comprenden y su uso en la preparacion de un medicamento para el tratamiento o profilaxis de la infeccion del hiv-1 o del sida | |
AR086676A1 (es) | Derivados de alcoholes 1-fenil-2-piridinil alquilicos como inhibidores de fosfodiesterasa | |
AR090945A1 (es) | Moduladores de la via del complemento y usos de los mismos | |
AR086100A1 (es) | Compuestos de cromenona y composiciones farmaceuticas que los contienen | |
BR112014023384A2 (pt) | inibidores de bace de di-hidro-tiazina e di-hidro-oxazina espirocíclicos, e composições e usos dos mesmos |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |